Stock data
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX) reported net income of -US$29.44M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$29.96M | -US$29.44M | — |
| 2024 | — | — | -US$22.67M | -US$21.61M | — |
| 2023 | — | — | -US$16.14M | -US$15.43M | — |
| 2022 | — | — | -US$8.22M | -US$8.23M | — |
| 2021 | — | — | -US$1.35M | -US$24.38M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$11.56M | — |
| 2026-03-31 | — | -US$10.09M | — |
| 2025-12-31 | — | -US$10.69M | — |
| 2025-09-30 | — | -US$7.59M | — |
| 2025-06-30 | — | -US$6.62M | — |
| 2025-03-31 | — | -US$4.54M | — |
| 2024-12-31 | — | -US$4.81M | — |
| 2024-09-30 | — | -US$7.15M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.